[stock_market_widget type="clock-markets" template="analog" timezone="America/New_York" title="New York" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/London" title="London" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Europe/Brussels" title="Brussels" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Hong_Kong" title="Hong Kong" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Asia/Tokyo" title="Tokyo" style="font-size: 7px; width: 100px;"] [stock_market_widget type="clock-markets" template="analog" timezone="Australia/Sydney" title="Sydney" style="font-size: 7px; width: 100px;"]

Stock Market News

Pfizer to spend $120 million to boost U.S. COVID pill manufacturing

06/06/2022

Less than a minute

2022.06.06 18:47

Pfizer to spend $120 million to boost U.S. COVID pill manufacturing
FILE PHOTO: The Pfizer logo is seen at the entrance to Pfizer UK headquarters in Tadworth, Britain, December 2, 2020. REUTERS/Peter Nicholls

(Reuters) – Pfizer Inc (NYSE:PFE) said on Monday it would spend $120 million to expand manufacturing of its COVID-19 antiviral treatment at its Michigan plant, as demand ramps up.

Use of the pill, Paxlovid, authorized to treat newly infected, at-risk people to prevent severe illness, has soared recently as infections rise.

Biden administration officials have pushed for the wider use of Paxlovid, which the government distributes for free.

Source

06/06/2022

Less than a minute